GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2013

Karo Wins First Milestone for Autoimmune Disease Deal with Pfizer

  • A success in the collaboration between Karo Bio and Pfizer to develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases has resulted in the first milestone payment to Karo.

    Under the deal, which began in December 2011, Pfizer agreed to provide full funding for the research costs and obtained the exclusive right to market any products that may be developed. For its efforts, Karo was promised up to $217 million in upfront and milestone payments in addition to potential royalty fees. A little more than two months ago, the original agreement was extended to the end of 2014.

    According to Karo, the nuclear hormone receptor RORgamma is an attractive target for the treatment of autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and psoriasis. RORgamma directly controls the production and secretion of the cytokine IL-17, a major contributor to inflammation. The receptor’s key role in driving disease pathology has been implicated in clinical trials using monoclonal antibodies that neutralize IL-17 activity. The agreement with Pfizer was entered into after Karo Bio discovered novel, potent, and specific RORgamma modulators.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »